Acadia Pharmaceuticals' drug remlifanserin missed the primary goal of a mid-stage Alzheimer's disease psychosis study, causing shares to drop about 11 per cent

BusinessSep 24 at 7:12 AM – Sep 24 at 10:37 AM3 outletsCanada

CTV News

Acadia’s Alzheimer’s psychosis drug misses main goal of mid-stage study seen Sep 24 at 10:37 AM

BNN Bloomberg

Acadia’s Alzheimer’s psychosis drug misses main goal of mid-stage study Sep 24 at 10:36 AM

Financial Post

Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer's Disease Psychosis (ADP) Sep 24 at 7:12 AM